After adjusting for potential confounders, multivariate analysis identified serum MXRA5 levels (OR = 1.018, 95 % CI 1.003–1.034) and perianal lesions (OR = 0.169, 95 % CI 0.029–0.971) as predictors of endoscopic response at week 24 in Crohn's Disease patients receiving IFX therapy. This evidence concerns the gene MXRA5 and Crohn disease.